Pim-1/3 kinase inhibitors (Theravalues)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NamePim-1/3 kinase inhibitors (Theravalues)
Drug Alias NamePim kinase inhibitors (Theravalues)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProto-oncogene serine/threonine-protein kinase Pim-1 inhibitorsSerine/threonine-protein kinase pim-3 inhibitors
TargetsProto-oncogene serine/threonine-protein kinase Pim-1Serine/threonine-protein kinase pim-3
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesTheravalues Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTheravalues Inc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A